Last reviewed · How we verify
Klebsiella Infections — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Coly-Mycin M | COLISTIMETHATE SODIUM | Ph Health | Polymyxin-class Antibacterial | 1970-01-01 | ||
| Coly-Mycin S | COLISTIN | Par Sterile Products | colistin | Melanocortin receptor 3 | 1962-01-01 | |
| colimycin | colimycin | Poitiers University Hospital | Melanocortin receptor 3, Melanocortin receptor 5, Epidermal growth factor receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Par Sterile Products · 1 drug in Klebsiella Infections
- Ph Health · 1 drug in Klebsiella Infections
- Poitiers University Hospital · 1 drug in Klebsiella Infections
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Klebsiella Infections:
- Klebsiella Infections treatment updates — RSS
- Klebsiella Infections treatment updates — Atom
- Klebsiella Infections treatment updates — JSON
Cite this brief
Drug Landscape (2026). Klebsiella Infections — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/klebsiella-infections. Accessed 2026-06-10.
Related
- Klebsiella Infections full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing